Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2024 Oct;205(4):1383-1388.
doi: 10.1111/bjh.19646. Epub 2024 Aug 1.

Long-term efficacy and safety of dose-dense and dose-intense ABVD without consolidation radiotherapy in patients with advanced Hodgkin lymphoma: A 15-year follow-up of the ABVDDD-DI phase II study

Gaetano Corazzelli  1 , Annarosa Cuccaro  1 , Emanuela Morelli  1 , Manuela Arcamone  1 , Annarosaria De Chiara  2 , Andrea Paccone  3 , Antonella Petrillo  4 , Francesco Ibello  5 , Corrado Aversa  6 , Maria Esposito  1 , Francesco Volzone  1 , Mariangela Saggese  1 , Gaetana Capobianco  1 , Sabrina Sarno  1 , Letizia Sirica  1 , Stefania Crisci  1 , Rosaria De Filippi  7 , Antonio Pinto  1
Affiliations
Clinical Trial

Long-term efficacy and safety of dose-dense and dose-intense ABVD without consolidation radiotherapy in patients with advanced Hodgkin lymphoma: A 15-year follow-up of the ABVDDD-DI phase II study

Gaetano Corazzelli et al. Br J Haematol. 2024 Oct.

Abstract

We demonstrated that dose-densified and dose-intensified ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine; ABVDDD-DI) was safe and effective. Here, we present a post hoc long-term analysis of the 82 patients enrolled in the original study. The median observation time was 175 months (IQR 159-197). At 15 years, progression-free and overall survival rates were 81.2% (95% CI, 69.9%-88.7%) and 92.7% (95% CI, 82.6%-97.0%), respectively. Four patients with multiple cardiovascular risk factors experienced delayed G3 cardiac events. The cumulative incidence of second malignancies at 20 years was 6.1%. Fertility and childbearing potential were unaffected. Data support an ongoing benefit for ABVDDD-DI without uneven late toxicities.

Keywords: ABVD; Hodgkin lymphoma; frontline intensification.

PubMed Disclaimer

References

REFERENCES

    1. Hanel W, Herrera AF, Epperla N. Management of classical Hodgkin lymphoma: a look at up to date evidence and current treatment approaches. Exp Hematol Oncol. 2022;11(1):108.
    1. Luminari S, Fossa A, Trotman J, Molin D, d'Amore F, Enblad G, et al. Long‐term follow‐up of the response‐adjusted therapy for advanced Hodgkin lymphoma trial. J Clin Oncol. 2024;42(1):13–18.
    1. Ansell SM, Radford J, Connors JM, Długosz‐Danecka M, Kim WS, Gallamini A, et al. Overall survival with brentuximab Vedotin in stage III or IV Hodgkin's lymphoma. N Engl J Med. 2022;387(4):310–320.
    1. Herrera AF, LeBlanc ML, Castellino SM, Li H, Rutherford SC, Evens AM, et al. SWOG S1826, a randomized study of nivolumab(N)‐AVD versus brentuximab vedotin(BV)‐AVD in advanced stage (AS) classic Hodgkin lymphoma (HL). J Clin Oncol. 2023;41(17_suppl):LBA4.
    1. Kreissl S, Goergen H, Buehnen I, Kobe C, Moccia A, Greil R, et al. PET‐guided eBEACOPP treatment of advanced‐stage Hodgkin lymphoma (HD18): follow‐up analysis of an international, open‐label, randomised, phase 3 trial. Lancet Haematol. 2021;8(6):e398–e409.

Publication types

MeSH terms

Supplementary concepts

LinkOut - more resources